 doi:10.20944/preprints202208.0278.v1

Review

Modulation of the Central Stress Response System to Prevent Complications of COVID-19 'Dam and Wall Concept'

Sanjiv K Hyoju[1,2]

[1] Surgical infection and therapeutic lab, Biological Science division, University of Chicago
[2] Bhomi Hospital and medical research institute, Banepa, Nepal
skhyoju@gmail.com; TEL.: 7184905674

Abstract: We are in amidst of COVID-19 pandemic. Since Dec 2019, severe acute respiratory corona virus (SAR-CoV-2) has infected more than half a billion people killing nearly 7 million people worldwide. Now the BA.5 variant of SARS-CoV-2 is causing mayhem and driving the global surge. Epidemiologist are aware of the fact that this virus is capable of escaping immunity and likely to infect the same person multiple times despite adequate vaccination status. Elderly people of age more than 60 years and those with underlying health conditions are considered as high-risk who are likely to suffer complications and death. While it is tempting to frame complications and mortality from COVID-19 as a simple matter of too much of a virulent virus in too weak of a host, much more is at play here. Framing the pathophysiology of COVID-19 in the context of the Chrousos and Gold model of the central stress response system can shed insight into its complex pathogenesis. Understanding the mechanisms by which pharmacologic modulation of the central stress response system via administration of clonidine and/or dexamethasone may offer an explanation as to why a viral pathogen can be well tolerated and cleared by one host while inflaming and killing another.

Keywords: central stress response system; sympathetic activity; HPA axis; SAR-CoV-2; catecholamine; corticosteriods; clonidine; dexamethasone

1. The role of sympathetic nervous system and hypothalamic-pituitary-adrenal (HPA) axes that drive homeostasis in the central stress response system

Body homeostasis is defined as complex dynamic yet balanced physical and biological status maintained by all living creatures for survival. The term was first coined by Walter Cannon [1]. Body homeostasis leading to uneventful recovery can become easily disrupted in the face of various intrinsic and extrinsic stressors such as bacterial and viral infections and environmental factors such as physical or psychological trauma. As a result, maladaptive responses can occur with unwanted neurohormonal immune activation that may continue inexorably until the perturbing forces are no longer present. This complex brain-body response is known as central stress system response as first described by Chrousos and Gold [2] [3]. In this model, two axes are primarily described, A) An autonomic sympathetic outflow axis also known as the locus coeruleus- norepinephrine axis (LC-NE/SNS); and B) CRH-cortisol also known as the Hypothalamic-pituitary-adrenal (HPA) axis. During stress, homeostasis to achieve recovery is achieved via fine-tuned control of the LC-NE/SNS and HPA axes so that they remained tightly coordinated in both intensity and duration and can converge to produce an appropriately measured response toward host recovery (Fig 1A).

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 16 August 2022 doi:10.20944/preprints202208.0278.v1



Figure 1A: Central processing of acute stress: Acute stress activates Locus coeruleus-Norepinephrine/Sympathetic nervous system (LC-NE/SNS) axis and hypothalamic-pituitary adrenal (HPA) axis to maintain homeostasis. Repetitive acute stress lead to peripheral adaptation.

The LC-NE/SNS axis is mediated by catecholamines. This system's input and output signals drive the interaction between the brain and the immune system. During acute stress, catecholamines surge in the body to prepare for a "fight and flight response" queueing up various behavior (increase arousal, alertness, loss of sleep and appetite) and physiological changes (increase heart rate and blood pressure). As a result, immunomodulatory pathways are activated via various adrenoreceptors (ARs) present on immune cells. Evidence for this coordinated response can be observed by sympathoadrenergic nerve fibers that are abundantly present on immune cells that respond to catecholamines released during stress [4]. Yet once this system is activated at the whole organ level, it can be both beneficial or deleterious depending on its intensity, duration and whether prior pre-conditioning of immune cells has occurred. Additionally, the density and affinity of ARs and the concentration of norepinephrine in local organs can differentially express the intensity of the immune response. For example, it has been shown that norepinephrine has preferentially stronger affinity for αARs 1 and 2 on immune cells resulting in a predominantly pro-inflammatory response. In contrast, high concentration of norepinephrine activates βARs [5] [6] [7]. β_2 adrenoreceptor activation inhibits the production of pro- inflammatory cytokines such as IL-12, TNFα, and interferon gamma while also stimulating the production of anti-inflammatory cytokine IL-10 [8]. Hence, depending upon the type of ARs population activated on immune cells, the immunomodulatory response might be either pro- or anti-inflammatory. Similarly, to the LC-NE/SNS axis, the HPA axis plays an equally important role in maintaining homeostasis following stress-

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 16 August 2022 doi:10.20944/preprints202208.0278.v1

related perturbations. The HPA axis increases peripheral levels of glucocorticoids (GCs). Glucocorticoids bind to intracellular glucocorticoids receptors (GRs) in peripheral immune cells and translocate to the nucleus; this downregulates NFκB pro-inflammatory genes transcription that can encode various cytokines such as IL-6, IL-1, TNF-α [9]. Thus, peripherally released glucocorticoids have a primarily anti-inflammatory effect. Likewise, both LC-NE/SNS and HPA axis play major role in redistributions of T cells. An increase in plasma cortisol reduces the blood lymphocyte count whereas catecholamines generally cause a leukocytosis. Both CD8+ T cells and natural kills cells rapidly yet transiently increase in the blood following catecholamine infusion which can be mitigated by catecholamine inhibition [10].

As a fight or flight response, sympathetic LC-NE/SNS axis activation not only prepares the body physically to manage stress, but it also induces a pro-inflammatory response that can decrescendo and shift to an anti-inflammatory response. Activation of the sympathetic LC-NE/SNS aims to localize the inflammatory response and protect the body from any detrimental effects of released pro-inflammatory cytokines [11]. Concomitant activation of an anti-inflammatory HPA axis further shuts down ongoing inflammation in an effort to maintain homeostasis by preventing excessive collateral damage to organs. Thus, there is coordination of both a central and peripheral stress response that adaptively interact to mitigate stress (Fig 1A).

2. Chronic stress disrupts the central stress response resulting in maladaptation and impaired recovery

Selye et al [12] defined the physiologic stress response as a biological phenomenon that seeks to balance host defense against the stressor while limiting internal damage. Repetitive and continuous stress eventually results in a maladaptive response to a harmful stimulus. Allostasis, the process by which the body responds to stressors in order to regain homeostasis [13] includes recalibration of the LC-NE/SNS axis and HPA axis to realign immunological functions of body toward recovery. An excessive "allostatic load" can result organ damage [14], despite the body continuing to calibrate itself to the continuous stressor [15]. Prolonged duration of the allostatic load can lead to complete failure of the system to recalibrate itself. In some cases, the LC-NE/SNS and HPA axes may develop a new set point [16] to minimize collateral damage. This causes an imbalance of central stress response system by affecting the calibrating efficiencies of these axes. Goldstein et al refer to this condition as dyshomeostasis [3]. The predominant outcomes in dyshomoestasis is overactivity of LC-NE/SNS axis perturbating immune cells function locally due to continuous low-grade release of norepinephrine (NE), leading to perhaps a "gain of function" outcome that is primarily pro-inflammatory. Such gain of function can augment the production of macrophage derived TNFα through α_2ARs [17], drive CD8+T lymphocytes toward more pro-inflammatory phenotype, and activate more β_2 adrenoreceptors on immune cell, producing a pro-inflammatory response instead of usual anti-inflammatory response [18, 19]. Another outcome is HPA axis overactivity lead to decrease sensitivity of glucocorticoids receptors to glucocorticoids, perhaps could be "loss of funtion" reducing its anti-inflammatory effects. Such biological changes attribute to pro-inflammatory phenotype [20]. Because of altered phenotype of immune cells during dyshomeostasis and superimposed stress due to virus infection [21], NE loses its ability to localize the inflammation and fails to protect the host from the detrimental effect of cytokines. Perhaps this response might be erratic and detrimental to health [22].

3. Body dyshomeostasis and the role of sympathetic hyperactivity

The current literature supports the notion that chronic health diseases such as obesity, hypertension, diabetes, autoimmune diseases and cardiovascular disease have been linked to chronic sympathetic hyperactivity and hence a chronic proinflammatory response [23]. The rapid evolution of civilization and its accompanying changes in living style, psychological stress, diet (i.e., Western diet consumption) and resultant dysbiosis

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 16 August 2022 doi:10.20944/preprints202208.0278.v1

[24] [25] [26] [27] are major contributors to the chronic disease state. As such, vulnerable populations are likely to be disproportionately impacted following any form of additional stress. A model developed in the Alverdy lab captures many of the features of this so called "dyshomeostasis" state. In this model, mice consuming their normally high fiber low fat of chow all survived after subjected to a major operative stress (i.e., a partial hepatectomy) whereas a 60-70% mortality rate was observed among similarly treated mice consuming a western type diet. Both groups of mice received antibiotics prior to operation, were starved overnight as in routine and underwent surgery under strict aseptic conditions. Yet the consumption of a western diet while led to such a dramatic alteration in outcome in this model such as dysbiosis and the emergence of a gut pathobiome that caused marked endogenously derived stress to the mice [28]. Intriguingly, this model may represent a state of dyshomeostasis induced obesity whereby there is chronic sympathetic hyperactive inflammation that contributes to the organ failure and death that is observed (Fig 1B).



Figure 1B. Imbalanced central stress response system during chronic stress with gain of function of Norepinephrine/Sympathetic nervous system (LC-NE/SNS) axis and loss of function of HPA axis causing dyshomeostasis. SARS-CoV-2 over activates LC-NE/SNS axis causing a pro-inflammatory catecholamine surge leading to organ damage in the susceptible person.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 16 August 2022 doi:10.20944/preprints202208.0278.v1

4. SARS-CoV2 imbalance central stress response system in vulnerable populations

It is noteworthy to acknowledge, that in the majority of patients who develop a SARS-CoV-2 infection, most remain asymptomatic or have mild symptoms. These populations are mainly young and healthy individual with presumably a balanced central stress response system. Older people and those living in a state of dyshomeostasis with underlying medical comorbidities are at risk of developing severe COVID-19 symptoms and are more predisposed to die from organ failure (Fig 1B). It has now been well established that COVID-19 cause autonomic nervous system dysfunction in human beings [29]. This is the neurotropic virus that is known to reach directly or indirectly to brainstem leading to impaired autonomic function with increasing sympathetic (SNS) axis hyperactivity [22] [30] [31] [32]. The pathogenesis of COVID-19 reveals a significant role of a sympathetic hyperactivity mediated imbalanced in Angiotensin converting enzyme 1 (ACE1) Vs ACE2 in the evolution of its disease sequalae and mortality [31] [33] [34] [35] (Fig 1b). One of the leading causes of death is hypoxia from acute respiratory distress syndrome secondary to viral pneumonia. One possibility to explain the differential response of young healthy versus older infirm patient's outcome following COVID-19 infection could be excessive reactive malfunction of the autonomic nervous system with sympathetic hyperactivity and hyperinflammation as observed for other infections [36]. For example, stellate ganglion blockade with local anesthesia to interrupt sympathetic outflow to lung has been proposed as an intervention to prevent acute respiratory distress syndrome [37]. Animal studies have demonstrated attenuation of acute lung injury following this approach [38]. Similarly, human long COVID-19 symptoms have been significantly improved after a similar intervention [39]. These observations may indicate a central theme across these disease states as applied to COVID-19 that the central stress response systems with LC_NE/SNS axis overactivation is a main driver for the immunopathology observed in COVID-19 pneumonia [31] [33]. Hypercoagulability, myocardial infraction, thrombosis and stroke are other spectrum of severe COVID-19 sequalae leading to morbidity and mortality. Biological markers in COVID-19, such as low platelets count deranged PT, PTT, protein C level and elevated D- dimer indicating coagulopathy, have been associated with increased circulating catecholamines [40] [41]. Similarly, an increased incidence of Takasubo cardiomyopathy in COVID-19 patients has been linked to cytokine storm and sympathetic hyperactivity related stress [42]. It is well known that increased catecholamines induces release of IL-6 and TNFα cytokines, causing leukopenia and orchestrating immune dysregulation, perpetuating cytokine storm through a self-amplifying loop within macrophages [43]. Such phenomena have been observed in COVID-19 patients. Disturbances of HPA/SNS axis responses have been implicated for the increase in C reactive protein, IL-6 and incidence of leukopenia in the setting of metabolic syndrome with chronic diseases [44]. Derangement of such biomarkers in chronic disease patients after infected with SAR-CoV-2 [45] is suggestive of exacerbation of disturbances in LC-NE/SNS and HPA axes response and thus may correlate with poor outcome [46] [45].

5. Clonidine and Dexamethasone acts synergistically to prevent complication during SAR-CoV-2 infection

We and others have previously hypothesized, that SARS-CoV-2 infection leads to overactivation of LC-NE/SNS axis and drives uncontrolled inflammation in the chronic sympathetic hyperactive population leading to poor outcome. Pharmacologic attenuation of LC-NE/SNS overactivation can be addressed by an FDA approved agent that targets the central sympathetic system, clonidine, an alpha$_2$ agonist that may have clinical benefit and prevent COVID-19 complications [22, 32, 34, 35] [47]. In a small case series, we demonstrated early administration of clonidine mitigated SARS-CoV-2 related symptoms thus preventing complications [47] . However, current practice is to use clonidine as sedative agent to respiratory distress patients in ICU set up [48]. Retrospective analysis done by Hamilton et al demonstrated that early used of an alpha$_2$ agonist is associated with

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 16 August 2022 doi:10.20944/preprints202208.0278.v1

reduced 28 days mortality and later use of the medication is not effective [49]. Baller et al recommended to use clonidine as prophylaxis against delirium in SARS-CoV-2 patients [50].

Counterintuitively, pharmacologic enhancement of the HPA axis with corticosteroid treatment has been found to be of clinical benefit in COVID-19 patients, however the timing of administration seems to play important role [51]. Multiple clinical trials have tested the effectiveness of dexamethasone in COVID-19 patients. The RECOVERY trial provided evidence that treatment with dexamethasone is beneficial for COVID-19 patients who required oxygen support although it was not helpful for those patients who did not require oxygen [52]. Although the CoDex randomized clinical trial demonstrated significant increase in the number of ventilator- free days over 28 days with dexamethasone treatment in moderate to severe COVID-19 patients, there was no difference in the mortality rate. Early treatment with dexamethasone has no added benefit in SARS-CoV-2 infection outcome, perhaps could possibly harm [53] the patients [54].

Taken together, much evidence suggests that disruption of central stress response system with gain of function of LC-NE/SNS axis and loss of function of HPA axis can lead to a worse outcome during the course of SARS-CoV-2 infection. Therefore, here I propose that timely administration of a combination of two drugs (clonidine and dexamethasone) in high risk patients has the potential to prevent complications and death (Fig 1C).



Figure 1C. Clonidine block LC-NE/SNS axis and dexamethasone enhance the HPA axis acting synergistically to balance the central stress response system during SARS-CoV-2 infection and prevent organ damage in dyshomeostatic person "Dam and Wall Concept".

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 16 August 2022 doi:10.20944/preprints202208.0278.v1

Clonidine has to start early during the course of disease in high risk population and increase gradually while monitoring blood pressure and heart rate. If the patient's condition has not improved or the patient requires oxygen, and/or has deranged biomarkers (i.e., increase IL-6, serum CRP, D-dimer, serum ferritin,), dexamethasone should be administrated without delay at a tolerable dosage (Fig 2).



Figure 2. Protocol design for initiation, maintenance and tapering of clonidine and dexamethasone for high risk SAR-CoV-2 positive patient.

A case has been discussed to further support the hypothesis. 54-year old over weight, female with past medical history of hypertension and depression, who tested positive for SAR-CoV-2 via nasopharyngeal swab PCR. She presented to emergency department with history of fever for 3-day, T-max up to 103°F, cough for 10 days, shortness of breath with excessive fatigue for 1day on august 3rd 2021 during acute surge of COVID-19 with delta variant. She was admitted in COVID ICU and started on continuous positive airway pressure (CPAP). She was on IV dexamethasone 6 mg twice daily along with board spectrum antibiotics, antifungal and heparin. Her condition deteriorated over the period of time requiring 80% FiO2 to maintain Sp02 above 90%. Blood tests demonstrated an elevated serum ferritin, D-dimer, CRP, PT, and LDH (Table 1). High resolution CT scan of chest demonstrated scattered areas of ground glass opacities and consolidation in bilateral lungs with subcutaneous emphysema with CT severity score of 24/25 and CORAD score 6 (Fig 3). Her condition was not improved and consulted us virtually on Day 15th of onset of symptoms. After explicitly consented, clonidine 100 microgram 8hourly was started on same day and gradually increased up to 200 microgram 6hourly by day 20th of onset of symptoms monitoring her heart rate and blood pressure. Both the hypoxia and tachypnea improved from day 21th onwards and clonidine and dexamethasone were tapered gradually and eventually stopped on day 30th.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 16 August 2022 doi:10.20944/preprints202208.0278.v1



Figure 3. High resolution CT scan of chest demonstrating scattered areas of ground glass opacities and consolidation in bilateral lungs with subcutaneous emphysema with CT severity score of 24/25 and CORAD score 6.

Table 1. Lab investigation of patient: Blood parameters CRP: c reactive protein, PT: prothrombin time, LDH: Lactate dehydrogenase.

Parameter		Normal range
Serum ferritin	1006.4	11.0-306ng/ml
D-dimer	4.6	<0.5mg/l
CRP	138.47	<10mg/dl
PT	20.5	11-16 sec
LDH	926	0-246ng/ml

Given the variable and potentially opposing effects of clonidine and dexamethasone, either drug alone may not be sufficient to control the ongoing inflammation. Randomized clinical trials to test the hypothesis that clonidine and dexamethasone can act synergistically to stop the ongoing overt inflammation centrally at the brainstem level and peripherally at the lung should be encouraged. Generation of the appropriate biomarkers and proper internal controls would yield considerable mechanistic information useful to those unfortunate individuals who develop severe symptoms following COVID-19 infection. This combined approach recapitulates the idea of "closing dam (centrally) and building wall (peripherally) to protect the home field (major organ)" from excessive adrenergic flooding (catecholamine). It should be emphasized that late administration of either drug is not beneficial as observed by other studies, since significant organ damage has already occurred.

6. Concluding Remark

The COVID-19 pandemic remains a clear and present danger to mankind. Multiple variants are now emerging and hospitalizations are increasing. In healthy population, repetitive infection with SAR-CoV-2 causes a flu like phenomenon because of a balanced central stress response system. With an imbalanced central stress response system, additional stress due to infection lead to substantial morbidity and mortality. Given the multiple ongoing emergence of new variants of SAR-CoV-2 virus, early recognition of high-risk patients whose response represents "dyshomeostasis" is critical and treatment with already available agents should be encouraged. Randomized clinical (CLODEX) trial using combination of clonidine and dexamethasone as mentioned in design protocol (Fig 3) is necessary to test this challenging "Dam and Wall" concept to prevent any further damage caused by emerging new variants of SARS-CoV-2 in high risk population.

Funding: This research received no funding support.

Informed Consent Statement: Informed consent has been taken form the patient, if require consent form is available with author.

Conflicts of Interest: Author declare no competing interest. Author continue treating COVID-19 patients in Nepal via Facebook based telehealth platform COVID-19 response group Nepal and Sanjiv Hyoju Free online health clinic Facebook page. The protocol has been drafted after gaining significant experience from treating COVID-19 patients.

References

1. Brown TM, Fee E. Walter Bradford Cannon: Pioneer Physiologist of Human Emotions. Am J Public Health. 2002;92(10):1594-5. PubMed PMID: PMC1447286.
2. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA. 1992;267(9):1244-52. Epub 1992/03/04. PubMed PMID: 1538563.
3. Goldstein DS. The extended autonomic system, dyshomeostasis, and COVID-19. Clin Auton Res. 2020;30(4):299-315. Epub 2020/07/24. doi: 10.1007/s10286-020-00714-0. PubMed PMID: 32700055; PubMed Central PMCID: PMCPMC7374073.
4. Bellinger DL, Lorton D, Felten SY, Felten DL. Innervation of lymphoid organs and implications in development, aging, and autoimmunity. Int J Immunopharmacol. 1992;14(3):329-44. Epub 1992/04/01. doi: 10.1016/0192-0561(92)90162-e. PubMed PMID: 1319962.
5. Pongratz G, Straub RH. The sympathetic nervous response in inflammation. Arthritis Res Ther. 2014;16(6):504. Epub 2014/01/01. doi: 10.1186/s13075-014-0504-2. PubMed PMID: 25789375; PubMed Central PMCID: PMCPMC4396833.
6. Grisanti LA, Woster AP, Dahlman J, Sauter ER, Combs CK, Porter JE. alpha1-adrenergic receptors positively regulate Toll-like receptor cytokine production from human monocytes and macrophages. J Pharmacol Exp Ther. 2011;338(2):648-57. Epub 2011/05/17. doi: 10.1124/jpet.110.178012. PubMed PMID: 21571945; PubMed Central PMCID: PMCPMC3141906.
7. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature. 2007;449(7163):721-5. Epub 2007/10/05. doi: 10.1038/nature06185. PubMed PMID: 17914358.
8. Swanson MA, Lee WT, Sanders VM. IFN-gamma production by Th1 cells generated from naive CD4+ T cells exposed to norepinephrine. J Immunol. 2001;166(1):232-40. Epub 2000/12/21. doi: 10.4049/jimmunol.166.1.232. PubMed PMID: 11123297.
9. Hermoso MA, Cidlowski JA. Putting the brake on inflammatory responses: the role of glucocorticoids. IUBMB Life. 2003;55(9):497-504. Epub 2003/12/09. doi: 10.1080/15216540310001642072. PubMed PMID: 14658755.
10. Dimitrov S, Benedict C, Heutling D, Westermann J, Born J, Lange T. Cortisol and epinephrine control opposing circadian rhythms in T cell subsets. Blood. 2009;113(21):5134-43. Epub 2009/03/19. doi: 10.1182/blood-2008-11-190769. PubMed PMID: 19293427; PubMed Central PMCID: PMCPMC2686184.
11. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595-638. Epub 2000/12/21. PubMed PMID: 11121511.
12. Selye H. Stress and the general adaptation syndrome. Br Med J. 1950;1(4667):1383-92. Epub 1950/06/17. doi: 10.1136/bmj.1.4667.1383. PubMed PMID: 15426759; PubMed Central PMCID: PMCPMC2038162.
13. Sterling P. Allostasis: a model of predictive regulation. Physiol Behav. 2012;106(1):5-15. Epub 2011/06/21. doi: 10.1016/j.physbeh.2011.06.004. PubMed PMID: 21684297.
14. McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci. 2006;8(4):367-81. Epub 2007/02/13. PubMed PMID: 17290796; PubMed Central PMCID: PMCPMC3181832.
15. McEwen BS. Stress, adaptation, and disease. Allostasis and allostatic load. Ann N Y Acad Sci. 1998;840:33-44. Epub 1998/06/18. doi: 10.1111/j.1749-6632.1998.tb09546.x. PubMed PMID: 9629234.
16. Harris RB. Role of set-point theory in regulation of body weight. FASEB J. 1990;4(15):3310-8. Epub 1990/12/01. doi: 10.1096/fasebj.4.15.2253845. PubMed PMID: 2253845.
17. Spengler RN, Allen RM, Remick DG, Strieter RM, Kunkel SL. Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J Immunol. 1990;145(5):1430-4. Epub 1990/09/01. PubMed PMID: 2166759.
18. Walsh CP, Ewing LJ, Cleary JL, Vaisleib AD, Farrell CH, Wright AGC, et al. Development of glucocorticoid resistance over one year among mothers of children newly diagnosed with cancer. Brain Behav Immun. 2018;69:364-73. Epub 2017/12/23. doi: 10.1016/j.bbi.2017.12.011. PubMed PMID: 29269321; PubMed Central PMCID: PMCPMC5857426.
19. Cole SW, Mendoza SP, Capitanio JP. Social stress desensitizes lymphocytes to regulation by endogenous glucocorticoids: insights from in vivo cell trafficking dynamics in rhesus macaques. Psychosom Med. 2009;71(6):591-7. Epub 2009/06/26. doi: 10.1097/PSY.0b013e3181aa95a9. PubMed PMID: 19553289; PubMed Central PMCID: PMCPMC3008298.
20. Walsh CP, Bovbjerg DH, Marsland AL. Glucocorticoid resistance and beta2-adrenergic receptor signaling pathways promote peripheral pro-inflammatory conditions associated with chronic psychological stress: A systematic review across species. Neurosci Biobehav Rev. 2021;128:117-35. Epub 2021/06/12. doi: 10.1016/j.neubiorev.2021.06.013. PubMed PMID: 34116126; PubMed Central PMCID: PMCPMC8556675.
21. Grebe KM, Takeda K, Hickman HD, Bailey AL, Embry AC, Bennink JR, et al. Cutting edge: Sympathetic nervous system increases proinflammatory cytokines and exacerbates influenza A virus pathogenesis. J Immunol. 2010;184(2):540-4. Epub 2009/12/19. doi: 10.4049/jimmunol.0903395. PubMed PMID: 20018617; PubMed Central PMCID: PMCPMC2941093.

22. Hyoju SK, Zaborina O, van Goor H. SARS-CoV-2 and the sympathetic immune response: Dampening inflammation with antihypertensive drugs (Clonidine and Propranolol). Med Hypotheses. 2020;144:110039. Epub 2020/08/08. doi: 10.1016/j.mehy.2020.110039. PubMed PMID: 32758881; PubMed Central PMCID: PMCPMC7834242.
23. Kopp W. Chronically increased activity of the sympathetic nervous system: our diet-related "evolutionary" inheritance. J Nutr Health Aging. 2009;13(1):27-9. Epub 2009/01/20. doi: 10.1007/s12603-009-0005-1. PubMed PMID: 19151904.
24. Murphy EA, Velazquez KT, Herbert KM. Influence of high-fat diet on gut microbiota: a driving force for chronic disease risk. Curr Opin Clin Nutr Metab Care. 2015;18(5):515-20. Epub 2015/07/15. doi: 10.1097/MCO.0000000000000209. PubMed PMID: 26154278; PubMed Central PMCID: PMCPMC4578152.
25. Carnagarin R, Lambert GW, Kiuchi MG, Nolde JM, Matthews VB, Eikelis N, et al. Effects of sympathetic modulation in metabolic disease. Ann N Y Acad Sci. 2019;1454(1):80-9. Epub 2019/08/20. doi: 10.1111/nyas.14217. PubMed PMID: 31424101.
26. Fisher JP, Young CN, Fadel PJ. Central sympathetic overactivity: maladies and mechanisms. Auton Neurosci. 2009;148(1-2):5-15. Epub 2009/03/10. doi: 10.1016/j.autneu.2009.02.003. PubMed PMID: 19268634; PubMed Central PMCID: PMCPMC2679852.
27. Snitker S, Macdonald I, Ravussin E, Astrup A. The sympathetic nervous system and obesity: role in aetiology and treatment. Obes Rev. 2000;1(1):5-15. Epub 2002/07/18. doi: 10.1046/j.1467-789x.2000.00001.x. PubMed PMID: 12119646.
28. Hyoju SK, Zaborin A, Keskey R, Sharma A, Arnold W, van den Berg F, et al. Mice Fed an Obesogenic Western Diet, Administered Antibiotics, and Subjected to a Sterile Surgical Procedure Develop Lethal Septicemia with Multidrug-Resistant Pathobionts. mBio. 2019;10(4). Epub 2019/08/01. doi: 10.1128/mBio.00903-19. PubMed PMID: 31363025; PubMed Central PMCID: PMCPMC6667615.
29. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond). 2021;21(1):e63-e7. Epub 2020/11/28. doi: 10.7861/clinmed.2020-0896. PubMed PMID: 33243837; PubMed Central PMCID: PMCPMC7850225.
30. Stute NL, Stickford JL, Province VM, Augenreich MA, Ratchford SM, Stickford ASL. COVID-19 is getting on our nerves: sympathetic neural activity and haemodynamics in young adults recovering from SARS-CoV-2. J Physiol. 2021;599(18):4269-85. Epub 2021/06/27. doi: 10.1113/JP281888. PubMed PMID: 34174086; PubMed Central PMCID: PMCPMC8447023.
31. Porzionato A, Emmi A, Barbon S, Boscolo-Berto R, Stecco C, Stocco E, et al. Sympathetic activation: a potential link between comorbidities and COVID-19. FEBS J. 2020;287(17):3681-8. Epub 2020/08/12. doi: 10.1111/febs.15481. PubMed PMID: 32779891; PubMed Central PMCID: PMCPMC7405290.
32. Al-Kuraishy HM, Al-Gareeb AI, Qusti S, Alshammari EM, Gyebi GA, Batiha GE. Covid-19-Induced Dysautonomia: A Menace of Sympathetic Storm. ASN Neuro. 2021;13:17590914211057635. Epub 2021/11/11. doi: 10.1177/17590914211057635. PubMed PMID: 34755562; PubMed Central PMCID: PMCPMC8586167.
33. Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251(3):228-48. Epub 2020/05/18. doi: 10.1002/path.5471. PubMed PMID: 32418199; PubMed Central PMCID: PMCPMC7276767.
34. Konig MF, Powell M, Staedtke V, Bai RY, Thomas DL, Fischer N, et al. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists. J Clin Invest. 2020;130(7):3345-7. Epub 2020/05/01. doi: 10.1172/JCI139642. PubMed PMID: 32352407; PubMed Central PMCID: PMCPMC7324164.
35. Gubbi S, Nazari MA, Taieb D, Klubo-Gwiezdzinska J, Pacak K. Catecholamine physiology and its implications in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(12):978-86. Epub 2020/11/01. doi: 10.1016/S2213-8587(20)30342-9. PubMed PMID: 33128872; PubMed Central PMCID: PMCPMC7598304.
36. Baker J, Incognito AV, Wilson RJA, Raj SR. Syncope and silent hypoxemia in COVID-19: Implications for the autonomic field. Auton Neurosci. 2021;235:102842. Epub 2021/07/12. doi: 10.1016/j.autneu.2021.102842. PubMed PMID: 34246957; PubMed Central PMCID: PMCPMC8258030.
37. Fischer L, Barop H, Ludin SM, Schaible HG. Regulation of acute reflectory hyperinflammation in viral and other diseases by means of stellate ganglion block. A conceptual view with a focus on Covid-19. Auton Neurosci. 2022;237:102903. Epub 2021/12/12. doi: 10.1016/j.autneu.2021.102903. PubMed PMID: 34894589.
38. Chen Y, Guo L, Lang H, Hu X, Jing S, Luo M, et al. Effect of a Stellate Ganglion Block on Acute Lung Injury in Septic Rats. Inflammation. 2018;41(5):1601-9. Epub 2018/05/09. doi: 10.1007/s10753-018-0803-x. PubMed PMID: 29737475.
39. Liu LD, Duricka DL. Stellate ganglion block reduces symptoms of Long COVID: A case series. J Neuroimmunol. 2022;362:577784. Epub 2021/12/19. doi: 10.1016/j.jneuroim.2021.577784. PubMed PMID: 34922127; PubMed Central PMCID: PMCPMC8653406.
40. Kearney TJ, Bentt L, Grode M, Lee S, Hiatt JR, Shabot MM. Coagulopathy and catecholamines in severe head injury. J Trauma. 1992;32(5):608-11; discussion 11-2. Epub 1992/05/01. doi: 10.1097/00005373-199205000-00012. PubMed PMID: 1588649.
41. Ikarugi H, Taka T, Nakajima S, Noguchi T, Watanabe S, Sasaki Y, et al. Norepinephrine, but not epinephrine, enhances platelet reactivity and coagulation after exercise in humans. J Appl Physiol (1985). 1999;86(1):133-8. Epub 1999/01/14. doi: 10.1152/jappl.1999.86.1.133. PubMed PMID: 9887123.
42. Shah RM, Shah M, Shah S, Li A, Jauhar S. Takotsubo Syndrome and COVID-19: Associations and Implications. Curr Probl Cardiol. 2021;46(3):100763. Epub 2020/12/29. doi: 10.1016/j.cpcardiol.2020.100763. PubMed PMID: 33360674; PubMed Central PMCID: PMCPMC7732220 competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

43. Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, Riggins GJ, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018;564(7735):273-7. Epub 2018/12/14. doi: 10.1038/s41586-018-0774-y. PubMed PMID: 30542164; PubMed Central PMCID: PMCPMC6512810.
44. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation. 2002;106(21):2659-65. Epub 2002/11/20. doi: 10.1161/01.cir.0000038364.26310.bd. PubMed PMID: 12438290.
45. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9. Epub 2020/03/29. doi: 10.1172/JCI137244. PubMed PMID: 32217835; PubMed Central PMCID: PMCPMC7190990.
46. Pal R. COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications. Endocrine. 2020;68(2):251-2. Epub 2020/04/30. doi: 10.1007/s12020-020-02325-1. PubMed PMID: 32346813; PubMed Central PMCID: PMCPMC7186765.
47. Hyoju SK, Baral B, Jha PK. Central catecholaminergic blockade with clonidine prevent SARS-CoV-2 complication: A case series. IDCases. 2021;25:e01219. Epub 2021/07/13. doi: 10.1016/j.idcr.2021.e01219. PubMed PMID: 34249614; PubMed Central PMCID: PMCPMC8258028.
48. Petitjeans F, Martinez JY, Danguy des Deserts M, Leroy S, Quintin L, Escarment J. A Centrally Acting Antihypertensive, Clonidine, Sedates Patients Presenting With Acute Respiratory Distress Syndrome Evoked by Severe Acute Respiratory Syndrome-Coronavirus 2. Crit Care Med. 2020;48(10):e991-e3. Epub 2020/07/04. doi: 10.1097/CCM.0000000000004503. PubMed PMID: 32618691; PubMed Central PMCID: PMCPMC7328439.
49. Hamilton JL, Vashi M, Kishen EB, Fogg LF, Wimmer MA, Balk RA. The Association of an Alpha-2 Adrenergic Receptor Agonist and Mortality in Patients With COVID-19. Front Med (Lausanne). 2021;8:797647. Epub 2022/01/22. doi: 10.3389/fmed.2021.797647. PubMed PMID: 35059419; PubMed Central PMCID: PMCPMC8764306.
50. Baller EB, Hogan CS, Fusunyan MA, Ivkovic A, Luccarelli JW, Madva E, et al. Neurocovid: Pharmacological Recommendations for Delirium Associated With COVID-19. Psychosomatics. 2020;61(6):585-96. Epub 2020/08/24. doi: 10.1016/j.psym.2020.05.013. PubMed PMID: 32828569; PubMed Central PMCID: PMCPMC7240270.
51. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683-4. Epub 2020/03/04. doi: 10.1016/S0140-6736(20)30361-5. PubMed PMID: 32122468; PubMed Central PMCID: PMCPMC7159292.
52. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. Epub 2020/07/18. doi: 10.1056/NEJMoa2021436. PubMed PMID: 32678530; PubMed Central PMCID: PMCPMC7383595.
53. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-5. Epub 2020/02/12. doi: 10.1016/S0140-6736(20)30317-2. PubMed PMID: 32043983; PubMed Central PMCID: PMCPMC7134694.
54. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020;324(13):1307-16. Epub 2020/09/03. doi: 10.1001/jama.2020.17021. PubMed PMID: 32876695; PubMed Central PMCID: PMCPMC7489411.